JPWO2023140329A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2023140329A5 JPWO2023140329A5 JP2023575297A JP2023575297A JPWO2023140329A5 JP WO2023140329 A5 JPWO2023140329 A5 JP WO2023140329A5 JP 2023575297 A JP2023575297 A JP 2023575297A JP 2023575297 A JP2023575297 A JP 2023575297A JP WO2023140329 A5 JPWO2023140329 A5 JP WO2023140329A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- active ingredient
- pharmaceutical composition
- mutant
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024135111A JP2024161461A (ja) | 2022-01-21 | 2024-08-13 | がんの治療または予防用医薬 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022008247 | 2022-01-21 | ||
| JP2022008247 | 2022-01-21 | ||
| EP22196417 | 2022-09-19 | ||
| EP22196417.4 | 2022-09-19 | ||
| PCT/JP2023/001552 WO2023140329A1 (ja) | 2022-01-21 | 2023-01-19 | がんの治療または予防用医薬 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024135111A Division JP2024161461A (ja) | 2022-01-21 | 2024-08-13 | がんの治療または予防用医薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2023140329A1 JPWO2023140329A1 (https=) | 2023-07-27 |
| JPWO2023140329A5 true JPWO2023140329A5 (https=) | 2024-08-06 |
| JP7540104B2 JP7540104B2 (ja) | 2024-08-26 |
Family
ID=87348318
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023575297A Active JP7540104B2 (ja) | 2022-01-21 | 2023-01-19 | がんの治療または予防用医薬 |
| JP2024135111A Pending JP2024161461A (ja) | 2022-01-21 | 2024-08-13 | がんの治療または予防用医薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024135111A Pending JP2024161461A (ja) | 2022-01-21 | 2024-08-13 | がんの治療または予防用医薬 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4467154A4 (https=) |
| JP (2) | JP7540104B2 (https=) |
| KR (2) | KR102857219B1 (https=) |
| AU (1) | AU2023208566A1 (https=) |
| IL (1) | IL313434A (https=) |
| MX (1) | MX2024008358A (https=) |
| TW (1) | TW202339786A (https=) |
| WO (1) | WO2023140329A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20221323A1 (es) | 2019-11-07 | 2022-09-09 | Chugai Pharmaceutical Co Ltd | Compuesto de peptidos ciclicos que tiene accion inhibidora de kras |
| TW202309065A (zh) | 2021-05-07 | 2023-03-01 | 日商中外製藥股份有限公司 | 包含n-取代胺基酸殘基之環狀化合物的製造方法 |
| CA3256645A1 (en) | 2022-05-06 | 2025-04-23 | Chugai Seiyaku Kabushiki Kaisha | CYCLIC COMPOUND HAVING A SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20230523T1 (hr) | 2013-09-06 | 2023-08-04 | Taiho Pharmaceutical Co., Ltd. | Antitumorski agens i sredstvo za poboljšavanje antitumorskog efekta |
| JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| WO2020165732A1 (en) * | 2019-02-12 | 2020-08-20 | Novartis Ag | Pharmaceutical combination comprising tno155 and a krasg12c inhibitor |
| WO2020205473A1 (en) * | 2019-03-29 | 2020-10-08 | Decerna Pharmaceuticals, Inc. | Compositions and methods for the treatment of kras associated diseases or disorders |
| EP4017454A4 (en) | 2019-08-19 | 2023-09-20 | Savvybaby Pty Ltd. | BABY BOTTLE AND ASSOCIATED VALVE SYSTEM |
| JP2021063014A (ja) | 2019-10-10 | 2021-04-22 | 国立大学法人 東京大学 | 白血病治療薬 |
| PE20221323A1 (es) * | 2019-11-07 | 2022-09-09 | Chugai Pharmaceutical Co Ltd | Compuesto de peptidos ciclicos que tiene accion inhibidora de kras |
| AR121078A1 (es) | 2020-01-22 | 2022-04-13 | Chugai Pharmaceutical Co Ltd | Derivados de arilamida con actividad antitumoral |
-
2023
- 2023-01-19 MX MX2024008358A patent/MX2024008358A/es unknown
- 2023-01-19 JP JP2023575297A patent/JP7540104B2/ja active Active
- 2023-01-19 KR KR1020247027102A patent/KR102857219B1/ko active Active
- 2023-01-19 TW TW112102786A patent/TW202339786A/zh unknown
- 2023-01-19 KR KR1020257029494A patent/KR20250135911A/ko active Pending
- 2023-01-19 WO PCT/JP2023/001552 patent/WO2023140329A1/ja not_active Ceased
- 2023-01-19 IL IL313434A patent/IL313434A/en unknown
- 2023-01-19 AU AU2023208566A patent/AU2023208566A1/en active Pending
- 2023-01-19 EP EP23743322.2A patent/EP4467154A4/en not_active Withdrawn
-
2024
- 2024-08-13 JP JP2024135111A patent/JP2024161461A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2023140329A5 (https=) | ||
| JP2019532051A5 (https=) | ||
| TW202339786A (zh) | 癌症之治療或預防用醫藥 | |
| AU2021280351A1 (en) | Methods of treating cancer in patients with an anomalous KRAS gene or deletions within chromosome 9 | |
| JP2018518529A5 (https=) | ||
| JP2024526135A (ja) | Ｅｒｋ１／２阻害剤とｋｒａｓ ｇ１２ｃ阻害剤の併用療法 | |
| US12281085B2 (en) | Bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof | |
| JP2025024064A (ja) | 癌治療 | |
| JP2021522340A (ja) | 精巣副腎残存腫瘍および卵巣副腎残存腫瘍を処置するための方法 | |
| TWI906448B (zh) | Kras g12c抑制劑在治療癌症中之用途 | |
| JP2021536507A (ja) | Ｈｅｒ駆動性がんを治療または予防するための化合物、組成物、及び方法 | |
| JPWO2022271964A5 (https=) | ||
| US12233072B2 (en) | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds for treating Adenoid Cystic Carcinoma | |
| BR112020023204A2 (pt) | composições que compreendem compostos de bisfluoroalquil-1,4-benzodiazepinona e métodos de uso dos mesmos | |
| Arora et al. | Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer | |
| JP2026016402A (ja) | 癌治療 | |
| TW201618785A (zh) | 使用ｅｒｋ抑制劑的治療方法 | |
| JP2016106092A (ja) | 組合せ | |
| JPWO2022170060A5 (https=) | ||
| SG11202112061RA (en) | Bisfluoroalkyl-1,4-benzodiazepin one compounds for treating notch-activated breast cancer | |
| JP6148320B2 (ja) | 組合せ | |
| CN116159062A (zh) | 药物组合物及其用途 | |
| US20240190858A1 (en) | Crystalline forms, pharmaceutical compositions and methods of use thereof | |
| CN120282786A (zh) | 治疗晚期实体肿瘤的方法 | |
| Wong et al. | Tivozanib for the treatment of metastatic renal cancer |